» Articles » PMID: 24681727

MAP4K4 Deletion Inhibits Proliferation and Activation of CD4(+) T Cell and Promotes T Regulatory Cell Generation in Vitro

Overview
Journal Cell Immunol
Publisher Elsevier
Date 2014 Apr 1
PMID 24681727
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

CD4(+) T cells are critical for adaptive immunity. MAP4K4 is a key member of germinal center kinase group. However, the physiological function of MAP4K4 in primary CD4(+) T cells is still unclear. In this study, it was demonstrated that in vitro, MAP4K4 deletion remarkably suppressed CD4(+) T cell proliferation in response to phorbol 12-myristate 13-acetate (PMA) and ionomycin, which was not due to enhancing cell apoptosis. Additionally, MAP4K4 was required for the activation of CD4(+) T cells. MAP4K4 deletion significantly down-regulated expression of interleukin 2 (IL-2) and interferon-γ (IFN-γ), while notably up-regulating the expression of regulatory T cells (Treg) transcription factor Foxp3 in peripheral CD4(+) T cells. Furthermore, western blot analysis indicated that CD4(+) T cells lacking MAP4K4 failed to phosphorylate Jnk, Erk, p38 and PKC-θ. Thus, our results provide the evidence that MAP4K4 is essential for CD4(+) T cell proliferation, activation and cytokine production.

Citing Articles

Overcoming radioresistance of breast cancer cells with MAP4K4 inhibitors.

Kwon Y, Lee M, Kim N, Nam G, Nam K, Jang H Sci Rep. 2024; 14(1):7410.

PMID: 38548749 PMC: 10978830. DOI: 10.1038/s41598-024-57000-6.


Editorial: Diverse roles of MAP4K4 in MAP kinase signaling and its implication for cancer therapeutics.

Roy R, Singh S, Rana A Front Oncol. 2023; 13:1248808.

PMID: 37546416 PMC: 10396797. DOI: 10.3389/fonc.2023.1248808.


Molecular Insights of MAP4K4 Signaling in Inflammatory and Malignant Diseases.

Singh S, Roy R, Kumar S, Srivastava P, Jha S, Rana B Cancers (Basel). 2023; 15(8).

PMID: 37190200 PMC: 10136566. DOI: 10.3390/cancers15082272.


The molecular basis of the dichotomous functionality of MAP4K4 in proliferation and cell motility control in cancer.

Jovanovic D, Yan S, Baumgartner M Front Oncol. 2022; 12:1059513.

PMID: 36568222 PMC: 9774001. DOI: 10.3389/fonc.2022.1059513.


Vascular smooth muscle RhoA counteracts abdominal aortic aneurysm formation by modulating MAP4K4 activity.

Molla M, Shimizu A, Komeno M, Rahman N, Chi Soh J, Nguyen L Commun Biol. 2022; 5(1):1071.

PMID: 36207400 PMC: 9546906. DOI: 10.1038/s42003-022-04042-z.